<p>中央太平洋銀行信託部門在最近向美國證券交易委員會提交的文件中表示，在第三季度將其在 Insulet Corporation（NASDAQ:PODD - 免費報告）中的股份減少了 99.8%。該基金在季度內出售了 291,000 股後，持有 480 股該醫療器械供應商的股票。中央太平洋銀行信託部門在 Insulet 的持股在最近一個季度末價值為 148,000 美元。</p>
<ul>
<li>2025 年表現優於市場的 3 只醫療科技股票</li>
</ul>
<p>其他一些機構投資者最近也買賣了 PODD 的股票。Kozak &amp; Associates Inc.在第二季度購買了 Insulet 的新股份，價值約為 32,000 美元。Golden State Wealth Management LLC 在第二季度將其在 Insulet 的股份增加了 202.9%。Golden State Wealth Management LLC 現在擁有 103 股該醫療器械供應商的股票，價值 32,000 美元，此前在上個季度又購買了 69 股。托萊多信託公司（Trust Co. of Toledo NA OH）在第二季度購買了 Insulet 的新股份，價值約為 35,000 美元。Osterweis Capital Management Inc.在第二季度購買了 Insulet 的新股份，價值約為 51,000 美元。最後，NewEdge Advisors LLC 在第一季度將其在 Insulet 的持股增加了 44.8%。NewEdge Advisors LLC 現在擁有 207 股該醫療器械供應商的股票，價值 54,000 美元，此前在此期間又購買了 64 股。</p>
<h2>Insulet 股票上漲 0.3%</h2>
<p>Insulet 股票週四開盤價為 289.57 美元。該公司的債務與股本比率為 0.68，流動比率為 2.87，速動比率為 2.18。該股票的市值為 203.7 億美元，市盈率為 83.93，PEG 比率為 2.03，貝塔值為 1.37。該公司的 50 日移動平均線為 317.47 美元，200 日移動平均線為 314.16 美元。Insulet Corporation 的 1 年最低價為 230.05 美元，1 年最高價為 354.88 美元。</p>
<ul>
<li>Insulet 在第一季度業績超預期，成為標準普爾 500 指數的頂尖表現者</li>
</ul>
<p>Insulet（NASDAQ:PODD - 獲取免費報告）最近在 11 月 6 日（星期四）發佈了季度財報。該醫療器械供應商報告季度每股收益為 1.24 美元，超出市場共識預期的 1.13 美元，超出幅度為 0.11 美元。Insulet 的淨利潤率為 9.76%，股本回報率為 24.36%。該公司在季度內的收入為 5.217 億美元，而分析師預期為 6.787 億美元。去年同期，該公司每股收益為 1.08 美元。公司的季度收入較去年同期增長了 29.9%。整體來看，研究分析師預計 Insulet Corporation 在本財年將發佈每股收益 3.92 美元。</p>
<h2>分析師評級調整</h2>
<p>幾位股票分析師對 PODD 股票發表了評論。BTIG Research 在 11 月 21 日的研究報告中將 Insulet 的目標價從 370.00 美元上調至 380.00 美元，並給予該公司 “買入” 評級。Jefferies Financial Group 在 11 月 6 日的報告中將 Insulet 的目標價從 375.00 美元上調至 400.00 美元，並給予該股票 “買入” 評級。Evercore ISI 在週二的研究報告中開始覆蓋 Insulet 股票，給予 “跑贏大盤” 評級和 370.00 美元的目標價。Oppenheimer 在 9 月 8 日的研究報告中將 Insulet 的目標價從 324.00 美元上調至 365.00 美元，並給予該公司 “跑贏大盤” 評級。最後，Rothschild &amp; Co Redburn 在 10 月 3 日的研究報告中將 Insulet 的目標價從 350.00 美元上調至 370.00 美元，並給予該股票 “買入” 評級。一位股票研究分析師給予該股票 “強烈買入” 評級，22 位給予 “買入” 評級，2 位給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 380.05 美元。</p>
<ul>
<li>這 5 只被低估的股票準備突破嗎？</li>
</ul>
<p><strong>獲取我們關於 Insulet 的最新研究報告</strong></p>
<h2>Insulet 公司簡介</h2>
<p>（免費報告）</p>
<p>Insulet Corporation 開發、製造和銷售用於胰島素依賴型糖尿病患者的胰島素輸送系統。該公司的 Omnipod 平台包括 Omnipod 5 自動胰島素輸送系統（Omnipod 5），該系統在 Pod 中嵌入了專有的 AID 算法，能夠與第三方連續血糖監測儀通過無線藍牙通信獲取血糖值；Omnipod DASH 具有藍牙功能的 Pod，由類似智能手機的個人糖尿病管理器控制，配備彩色觸摸屏用户界面；以及 Omnipod GO，一種獨立的可穿戴胰島素輸送系統，提供 72 小時的持續快速作用胰島素固定速率。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票比 Insulet 更具吸引力</li>
<li>股息篩選器：如何在購買前評估股息股票</li>
<li>在上漲 35% 後，分析師關注銅業巨頭 Freeport 的更多上漲空間</li>
<li>價值投資：在 2022 年這是一種好策略嗎？提示：永遠</li>
<li>為什麼 SpaceX 的 IPO 可能成為 GOOGL 股票的重大催化劑</li>
<li>5 只值得考慮的高評級股息股票</li>
<li>Upwork 能否維持其復甦？看漲和看跌的理由</li>
</ul>
<p><strong>想看看其他對 PODD 持有股份的對沖基金嗎？</strong> 訪問 HoldingsChannel.com，獲取 Insulet Corporation（NASDAQ:PODD - 免費報告）的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UE9ERA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UE9ERA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Insulet 嗎？</h2>
<p>在考慮 Insulet 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Insulet 並不在名單上。</p>
<p>雖然 Insulet 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

PODD

<p>中央太平洋銀行信託部門在第三季度將其在 Insulet Corporation 的持股減少了 99.8%，出售了 291,000 股，保留了 480 股，價值為 148,000 美元。儘管如此，Insulet 的股票表現依然強勁，分析師維持 “適度買入” 評級，普遍目標價為 380.05 美元。該公司報告的季度收入同比增長 29.9%</p>

<p>Central Pacific Bank Trust Division lowered its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 99.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 480 shares of the medical instruments supplier's stock after selling 291,000 shares during the quarter. Central Pacific Bank Trust Division's holdings in Insulet were worth $148,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>中央太平洋銀行信託部門在最近向美國證券交易委員會提交的文件中表示，在第三季度將其在 Insulet Corporation（NASDAQ:PODD - 免費報告）中的股份減少了 99.8%。該基金在季度內出售了 291,000 股後，持有 480 股該醫療器械供應商的股票。中央太平洋銀行信託部門在 Insulet 的持股在最近一個季度末價值為 148,000 美元。</p>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年表現優於市場的 3 只醫療科技股票</li>
</ul>
</div><p>A number of other institutional investors also recently bought and sold shares of PODD. Kozak &amp; Associates Inc. bought a new stake in shares of Insulet in the 2nd quarter worth about $32,000. Golden State Wealth Management LLC lifted its stake in Insulet by 202.9% in the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier's stock worth $32,000 after purchasing an additional 69 shares during the last quarter. Trust Co. of Toledo NA OH purchased a new position in shares of Insulet during the second quarter valued at approximately $35,000. Osterweis Capital Management Inc. bought a new position in shares of Insulet during the second quarter valued at approximately $51,000. Finally, NewEdge Advisors LLC raised its holdings in shares of Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier's stock worth $54,000 after buying an additional 64 shares during the period.</p>
<div class="lb-trans"><p>其他一些機構投資者最近也買賣了 PODD 的股票。Kozak &amp; Associates Inc.在第二季度購買了 Insulet 的新股份，價值約為 32,000 美元。Golden State Wealth Management LLC 在第二季度將其在 Insulet 的股份增加了 202.9%。Golden State Wealth Management LLC 現在擁有 103 股該醫療器械供應商的股票，價值 32,000 美元，此前在上個季度又購買了 69 股。托萊多信託公司（Trust Co. of Toledo NA OH）在第二季度購買了 Insulet 的新股份，價值約為 35,000 美元。Osterweis Capital Management Inc.在第二季度購買了 Insulet 的新股份，價值約為 51,000 美元。最後，NewEdge Advisors LLC 在第一季度將其在 Insulet 的持股增加了 44.8%。NewEdge Advisors LLC 現在擁有 207 股該醫療器械供應商的股票，價值 54,000 美元，此前在此期間又購買了 64 股。</p>
</div><h2>Insulet Stock Up 0.3%</h2>
<div class="lb-trans"><h2>Insulet 股票上漲 0.3%</h2>
</div><p>Shares of Insulet stock opened at $289.57 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18. The stock has a market cap of $20.37 billion, a price-to-earnings ratio of 83.93, a PEG ratio of 2.03 and a beta of 1.37. The firm's 50-day moving average is $317.47 and its two-hundred day moving average is $314.16. Insulet Corporation has a 1 year low of $230.05 and a 1 year high of $354.88.</p>
<div class="lb-trans"><p>Insulet 股票週四開盤價為 289.57 美元。該公司的債務與股本比率為 0.68，流動比率為 2.87，速動比率為 2.18。該股票的市值為 203.7 億美元，市盈率為 83.93，PEG 比率為 2.03，貝塔值為 1.37。該公司的 50 日移動平均線為 317.47 美元，200 日移動平均線為 314.16 美元。Insulet Corporation 的 1 年最低價為 230.05 美元，1 年最高價為 354.88 美元。</p>
</div><ul>
<li>Insulet Surges on Q1 Beat, Emerges as a Top S&amp;P 500 Performer</li>
</ul>
<div class="lb-trans"><ul>
<li>Insulet 在第一季度業績超預期，成為標準普爾 500 指數的頂尖表現者</li>
</ul>
</div><p>Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating the consensus estimate of $1.13 by $0.11. Insulet had a net margin of 9.76% and a return on equity of 24.36%. The business had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. During the same quarter in the previous year, the business posted $1.08 EPS. The company's quarterly revenue was up 29.9% compared to the same quarter last year. As a group, research analysts expect that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Insulet（NASDAQ:PODD - 獲取免費報告）最近在 11 月 6 日（星期四）發佈了季度財報。該醫療器械供應商報告季度每股收益為 1.24 美元，超出市場共識預期的 1.13 美元，超出幅度為 0.11 美元。Insulet 的淨利潤率為 9.76%，股本回報率為 24.36%。該公司在季度內的收入為 5.217 億美元，而分析師預期為 6.787 億美元。去年同期，該公司每股收益為 1.08 美元。公司的季度收入較去年同期增長了 29.9%。整體來看，研究分析師預計 Insulet Corporation 在本財年將發佈每股收益 3.92 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>Several equities analysts have commented on PODD shares. BTIG Research upped their price objective on Insulet from $370.00 to $380.00 and gave the company a &#34;buy&#34; rating in a research report on Friday, November 21st. Jefferies Financial Group upped their price target on shares of Insulet from $375.00 to $400.00 and gave the stock a &#34;buy&#34; rating in a report on Thursday, November 6th. Evercore ISI started coverage on shares of Insulet in a research note on Tuesday. They issued an &#34;outperform&#34; rating and a $370.00 price target on the stock. Oppenheimer boosted their price objective on shares of Insulet from $324.00 to $365.00 and gave the company an &#34;outperform&#34; rating in a research report on Monday, September 8th. Finally, Rothschild &amp; Co Redburn raised their target price on shares of Insulet from $350.00 to $370.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $380.05.</p>
<div class="lb-trans"><p>幾位股票分析師對 PODD 股票發表了評論。BTIG Research 在 11 月 21 日的研究報告中將 Insulet 的目標價從 370.00 美元上調至 380.00 美元，並給予該公司 “買入” 評級。Jefferies Financial Group 在 11 月 6 日的報告中將 Insulet 的目標價從 375.00 美元上調至 400.00 美元，並給予該股票 “買入” 評級。Evercore ISI 在週二的研究報告中開始覆蓋 Insulet 股票，給予 “跑贏大盤” 評級和 370.00 美元的目標價。Oppenheimer 在 9 月 8 日的研究報告中將 Insulet 的目標價從 324.00 美元上調至 365.00 美元，並給予該公司 “跑贏大盤” 評級。最後，Rothschild &amp; Co Redburn 在 10 月 3 日的研究報告中將 Insulet 的目標價從 350.00 美元上調至 370.00 美元，並給予該股票 “買入” 評級。一位股票研究分析師給予該股票 “強烈買入” 評級，22 位給予 “買入” 評級，2 位給予 “持有” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為 380.05 美元。</p>
</div><ul>
<li>Are These 5 Undervalued Stocks Ready to Break Out?</li>
</ul>
<div class="lb-trans"><ul>
<li>這 5 只被低估的股票準備突破嗎？</li>
</ul>
</div><p><strong>Get Our Latest Research Report on Insulet</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Insulet 的最新研究報告</strong></p>
</div><h2>Insulet Profile</h2>
<div class="lb-trans"><h2>Insulet 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.</p>
<div class="lb-trans"><p>Insulet Corporation 開發、製造和銷售用於胰島素依賴型糖尿病患者的胰島素輸送系統。該公司的 Omnipod 平台包括 Omnipod 5 自動胰島素輸送系統（Omnipod 5），該系統在 Pod 中嵌入了專有的 AID 算法，能夠與第三方連續血糖監測儀通過無線藍牙通信獲取血糖值；Omnipod DASH 具有藍牙功能的 Pod，由類似智能手機的個人糖尿病管理器控制，配備彩色觸摸屏用户界面；以及 Omnipod GO，一種獨立的可穿戴胰島素輸送系統，提供 72 小時的持續快速作用胰島素固定速率。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Insulet</li>
<li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li>
<li>Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport</li>
<li>Value Investing: Is it a Good Strategy in 2022? Hint: Always</li>
<li>Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Insulet 更具吸引力</li>
<li>股息篩選器：如何在購買前評估股息股票</li>
<li>在上漲 35% 後，分析師關注銅業巨頭 Freeport 的更多上漲空間</li>
<li>價值投資：在 2022 年這是一種好策略嗎？提示：永遠</li>
<li>為什麼 SpaceX 的 IPO 可能成為 GOOGL 股票的重大催化劑</li>
<li>5 只值得考慮的高評級股息股票</li>
<li>Upwork 能否維持其復甦？看漲和看跌的理由</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PODD?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對 PODD 持有股份的對沖基金嗎？</strong> 訪問 HoldingsChannel.com，獲取 Insulet Corporation（NASDAQ:PODD - 免費報告）的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UE9ERA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=PODD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Insulet Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Insulet 嗎？</h2>
</div><p>Before you consider Insulet, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Insulet 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Insulet 並不在名單上。</p>
</div><p>While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Insulet 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

中央太平洋銀行信託部門減少了其在 Insulet Corporation $PODD 的股票持有量